/KALV
KALV Stock - KalVista Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$14.94-8.85%
$1.45 (-8.85%) • Jan 13
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.74
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+116.4%upside
Target: $32.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KALV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.79 – $15.09
TARGET (TP)$32.33
STOP LOSS$13.74
RISK/REWARD1:14.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.15
52W High$19.00
52W Low$7.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-86,167,000 | N/A | N/A | $-41,286,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-187,995,000 | $-140,445,000 | $-110,871,000 | $-96,613,000 | $-57,923,000 |
| Net Income | $-183,444,000 | $-126,644,000 | $-92,907,000 | $-82,339,000 | $-46,244,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.33 |
Company Overview
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
KALVBeat Rate
47%
Last 19 quarters
Avg Surprise
-1.7%
EPS vs Estimate
Beats / Misses
9/9
1 met exactly
Latest EPS
$-0.92
Q4 2025
EPS Surprise History
Q1 24
-12.4%
$-0.84vs$-0.75
Q3 24
-43.7%
$-1.02vs$-0.71
Q3 24
+8.4%
$-0.87vs$-0.95
Q4 24
0.0%
$-0.91vs$-0.91
Q1 25
-3.4%
$-0.92vs$-0.89
Q3 25
-28.6%
$-0.99vs$-0.77
Q3 25
-23.1%
$-1.12vs$-0.91
Q4 25
+4.2%
$-0.92vs$-0.96
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.96 | $-0.92 | +4.2% | ✓ BEAT |
Q3 2025 | Sep 11, 2025 | $-0.91 | $-1.12 | -23.1% | ✗ MISS |
Q3 2025 | Jul 10, 2025 | $-0.77 | $-0.99 | -28.6% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.89 | $-0.92 | -3.4% | ✗ MISS |
Q4 2024 | Dec 5, 2024 | $-0.91 | $-0.91 | 0.0% | = MET |
Q3 2024 | Sep 5, 2024 | $-0.95 | $-0.87 | +8.4% | ✓ BEAT |
Q3 2024 | Jul 11, 2024 | $-0.71 | $-1.02 | -43.7% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.75 | $-0.84 | -12.4% | ✗ MISS |
Q4 2023 | Dec 7, 2023 | $-0.71 | $-0.80 | -12.7% | ✗ MISS |
Q3 2023 | Sep 7, 2023 | $-0.83 | $-0.74 | +10.8% | ✓ BEAT |
Q3 2023 | Jul 7, 2023 | $-0.92 | $-0.77 | +16.3% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.97 | $-0.75 | +22.7% | ✓ BEAT |
Q4 2022 | Dec 8, 2022 | $-1.04 | $-0.90 | +13.5% | ✓ BEAT |
Q3 2022 | Sep 8, 2022 | $-1.02 | $-0.94 | +7.8% | ✓ BEAT |
Q3 2022 | Jul 7, 2022 | $-1.06 | $-0.98 | +7.5% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.91 | $-0.92 | -1.1% | ✗ MISS |
Q4 2021 | Dec 9, 2021 | $-0.78 | $-0.80 | -2.6% | ✗ MISS |
Q3 2021 | Sep 9, 2021 | $-0.73 | $-0.66 | +9.6% | ✓ BEAT |
Q3 2021 | Jul 13, 2021 | $-0.61 | $-0.65 | -6.6% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about KALV
What is KALV's current stock price?
KalVista Pharmaceuticals, Inc. (KALV) is currently trading at $14.94 per share. The stock has moved -8.85% today.
What is the analyst price target for KALV?
The average analyst price target for KALV is $32.33, based on 1 analyst.
What sector is KalVista Pharmaceuticals, Inc. in?
KalVista Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KALV's market cap?
KalVista Pharmaceuticals, Inc. has a market capitalization of $0.76 billion, making it a small-cap company.
Does KALV pay dividends?
No, KalVista Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.70
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.49
Mkt Cap: $0.4B
FDMT
4D Molecular Therapeutics, Inc.
$7.86
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$2.66
Mkt Cap: $0.6B
OLMA
Olema Pharmaceuticals, Inc.
$27.89
Mkt Cap: $1.9B
OMER
Omeros Corporation
$12.62
Mkt Cap: $0.9B
PRTA
Prothena Corporation plc
$8.98
Mkt Cap: $0.5B
RAPT
RAPT Therapeutics, Inc.
$34.06
Mkt Cap: $0.6B
RIGL
Rigel Pharmaceuticals, Inc.
$37.96
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.20
Mkt Cap: $0.4B
Explore stocks similar to KALV for comparison